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SUMMARY

Histone citrullination regulates diverse cellular processes. Here, we report that SMARCAD1 preferentially associates with H3 arginine 26 citrullination
(H3R26Cit) peptides present on arrays composed of
384 histone peptides harboring distinct post-transcriptional modifications. Among ten histone modifications assayed by ChIP-seq, H3R26Cit exhibited
the most extensive genomewide co-localization with
SMARCAD1 binding. Increased Smarcad1 expression correlated with naive pluripotency in pre-implantation embryos. In the presence of LIF, Smarcad1
knockdown (KD) embryonic stem cells lost naive state
phenotypes but remained pluripotent, as suggested
by morphology, gene expression, histone modifications, alkaline phosphatase activity, energy metabolism, embryoid bodies, teratoma, and chimeras.
The majority of H3R26Cit ChIP-seq peaks occupied
by SMARCAD1 were associated with increased levels
of H3K9me3 in Smarcad1 KD cells. Inhibition of H3Cit
induced H3K9me3 at the overlapping regions of
H3R26Cit peaks and SMARCAD1 peaks. These data
suggest a model in which SMARCAD1 regulates naive
pluripotency by interacting with H3R26Cit and suppressing heterochromatin formation.
INTRODUCTION
Histone citrullination, also called deimination, is a post-translational conversion of arginine into the amino acid citrulline (Klose

and Zhang, 2007). The functional importance of H3 citrullination
(H3Cit) includes regulation of naive pluripotency (Christophorou
et al., 2014), gene regulation in cancer (Zhang et al., 2012), immune response (Neeli et al., 2008), and autoimmune disease
(Sharma et al., 2012). However, the mechanisms underlying histone-citrullination-mediated regulation of cell physiology remain
elusive. The available information includes that citrullination is
antagonistic to arginine methylation (Cuthbert et al., 2004) and
negatively regulates chromatin compaction (Christophorou
et al., 2014), partially by weakening H3K9me3-mediated heterochromatin formation (Sharma et al., 2012). It is unknown whether
any protein could read histone citrullination and relay its regulatory signal.
To search for proteins that may interact with citrullinated histones, we leveraged the discovery that H3Cit is associated
with the establishment of naive pluripotency during embryonic
development and cellular reprogramming (Christophorou et al.,
2014). We searched for proteins that can be attached to chromatin and that are correlated with the establishments of inner
cell mass (ICM) and naive-state pluripotent stem cells. This
search identified two genes, with temporal expression patterns
that peak at blastocyst stage and that are elevated in the ICM,
that share sequence similarities with chromatin modification protein genes. These genes are Smarca4 (a.k.a. Brg1) and Smarcad1. Because the role of Smarca4 on embryonic stem cell
(ESC) regulation has been characterized and the published
data do not involve H3Cit (Kidder et al., 2009), we focused on
the less studied Smarcad1.
Smarcad1, a.k.a. Etl1 or Hel1, is one of the mammalian
SNF2 family genes (Soininen et al., 1992). It contains DEAD/H
ATP-binding domains and a bipartite nuclear localization
signal (Schoor et al., 1993; Adra et al., 2000). It is expressed
in all assayed embryonic and adult tissues (Adra et al., 2000),
but its expression levels are exceptionally high in embryonal,

Cell Reports 18, 3117–3128, March 28, 2017 ª 2017 The Author(s). 3117
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

mammary, and lymphoid tumors (Okazaki et al., 2008).
SMARCAD1 is attached to chromatin in both cancer
and normal cells (Okazaki et al., 2008; Rowbotham et al.,
2011).
RESULTS
Increased SMARCAD1 Expression Is Associated with
Naive Pluripotency in Developing Embryos and in Cell
Culture
We analyzed the association between Smarcad1 expression
levels and pluripotent states in mouse and human preimplantation embryos. We generated RNA sequencing (RNA-seq) data
from the ICM and the whole blastocyst of preimplantation
mouse embryos. Smarcad1 was expressed 2.7 times higher in
ICM (RPKM [reads per kilobase per million] = 132.4) than in
the whole blastocyst (RPKM = 49.4) (Figure 1A). Consistently,
in a published RNA-seq dataset (Tang et al., 2010), Smarcad1
exhibited 1.5 times higher expression in the ICM than in trophectoderm. Next, we re-analyzed our previously generated
gene expression data from mouse preimplantation embryos at
seven developmental stages with three biological replicates at
each stage (Xie et al., 2010). Smarcad1 mRNA was strongly
and reproducibly induced at the eight-cell stage (Figure 1B),
approximately 2 days prior to implantation. At the blastocyst
stage, mouse SMARCAD1 protein expression is restricted to
the ICM (see Figure 4 of Schoor et al. [1993]). In a single-cell
RNA-seq dataset from human preimplantation embryos (GEO:
GSE36552) (Yan et al., 2013), SMARCAD1 expression
increased from the two-cell stage to the blastocyst stage,
peaking in some single cells in morula and in ICM (Figure 1C).
All human mural trophectoderm cells except one had low
SMARCAD1 expression (Figure 1C). Human 32-cell morula is
formed approximately 2 days prior to implantation (Cockburn
and Rossant, 2010); therefore, the SMARCAD1 mRNA peaked
at approximately the same amount of time prior to implantation
in mice and in humans.
Furthermore, we tested the association between Smarcad1
expression and pluripotent states using various cell lines.
SMARCAD1 protein levels were significantly higher in mouse
ES cells (naive state) than in epiblast-derived stem cells
(EpiSCs, primed state) (Figure 1D). In humans, SMARCAD1
mRNA was more abundant in naive cells as compared to
primed embryonic stem cells (ESCs) (RNA-seq data from
ArrayExpress: E-MTAB-2857 [Takashima et al., 2014], p =
0.012, two-tailed t test). In addition, our western blots suggest
that SMARCAD1 proteins were more abundant in pig naive
ESCs (Telugu et al., 2011) than in the primed pig induced
pluripotent stem cells (iPSCs) (Ezashi et al., 2009; Figure 1E).
We do not have the data to directly compare Smarcad1
expression levels in preimplantation ICM and postimplantation
epiblasts. However, re-analysis of a published microarray dataset (Tesar et al., 2007) suggested higher Smarcad1 mRNA
expression in ESCs than in postimplantation epiblasts (p =
0.00039) or in EpiSCs (p = 0.00015) (Figure 1F). Taken
together, higher Smarcad1 mRNA and protein levels are associated with naive pluripotent stem cells in developing embryos
and in cell culture.
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SMARCAD1 Possesses Binding Specificity to Histone
Modification but Not to DNA Sequence
SMARCAD1 binds to chromatin (Okazaki et al., 2008; Rowbotham et al., 2011). To determine whether the specificity of
SMARCAD1-chromatin interaction is achieved by SMARCAD1’s
recognition of specific DNA sequences, we carried out highthroughput SELEX (HT-SELEX) (Zhao et al., 2009) with two randomized sequence libraries, one with a 10-bp and the other
with a 20-bp randomized region. HT-SELEX was performed for
two rounds on each of the two libraries. Neither selection enriched for any sequence motif, suggesting that the SMARCAD1
protein used in this study does not recognize specific DNA
sequences.
We then asked whether SMARCAD1 recognizes specific
histone post-translational modifications. We incubated
SMARCAD1 with two MODified Histone Peptide Arrays. Each
array contained 384 19-mer histone peptides. Each peptide
is an N-terminal tail of H2A, H2B, H3, or H4, with a unique combination of post-translational modifications (Active Motif,
2014). The two arrays exhibited reproducible binding signals,
and they consistently identified the peptide with a single modification (H3R26Cit) as the strongest binding peptide (Figure 2A). We then compared the post-translationally modified
peptides to those with the same amino-acid sequence without
any modification by calculating the ratio of the binding signals
between every modified peptide and its unmodified counterpart. H3R26Cit exhibited the largest binding increment (ratio)
to the unmodified peptide, followed by H3K27ac; however,
only the H3R26Cit peptide exhibited 3-fold or larger binding
signals than the background peptides in both arrays (Figures
2B and S1). These data prioritize H3R26Cit followed by
H3K27ac as histone modifications that SMARCAD1 may preferentially associate with in vitro.
SMARCAD1 Co-localizes with H3R26Cit on the Genome
The in-vitro-binding specificity led us to posit that SMARCAD1
binds to chromatin with H3R26Cit or H3K27ac in vivo. To test
this, we carried out chromatin immunoprecipitation (ChIP)
sequencing (ChIP-seq) on H3R26Cit (Abcam: ab19847) (Zhang
et al., 2012) and SMARCAD1 (Abcam: ab67548) in mouse
ESCs. These data were jointly analyzed with our published
ChIP-seq datasets for nine other histone modifications from
the same cell line, including H3K27ac, H2A.Z, H3K4me1,
H3K4me2, H3K4me3, H3K9me3, H3K27me3, H3K36me3, and
5-mC (MeDIP-seq [methylated DNA immunoprecipitation followed by sequencing]) (Xiao et al., 2012; Figure S2A). The extent
of H3K27ac-SMARCAD1 co-localization was 4.6-fold greater
than expectation (odds ratio = 4.56; Figure 2C, blue bars).
Among the ten histone modifications, H3R26Cit exhibited the
strongest co-localization with SMARCAD1 (odds ratio = 9.94,
p < 10 20, chi-square test) (Figure 2C, blue bars). These data
suggest a genomewide correlation of H3 citrullination and
SMARCAD1 binding in ESCs.
We used OCT4 ChIP-seq (Xiao et al., 2012) as another control
to further assess the specificity of the genomewide co-localization of SMARCAD1 binding with any the ten histone modifications. OCT4 and SMARCAD1 exhibited similar degrees of colocalization (odds ratio z 1) with nine of the ten histone marks

Figure 1. Smarcad1 Expression Patterns in Early Embryonic Development and in Pluripotent Stem Cells
(A) RNA-seq-derived Smarcad1 mRNA levels in ICM, whole blastocyst, trophectoderm, and epiblast. dpc, days post-conception.
(B) Expression heatmap of genes related to DNA methylation, H3K9 methylation, and histone citrullination. Three biological replicates (a, b, and c) were analyzed
in each of seven stages in mouse preimplantation development. L-Morula, late morula stage. Gene expression levels were normalized across samples, clustered
(dendrogram), and visualized (yellow, high expression; blue, low expression).
(C) SMARCAD1 expression (y axis) in single cells of human preimplantation embryos (GEO: GSE36552). Each column represents a single cell, and the cells were
grouped by developmental stage (x axis). TE, trophectoderm.
(D and E) Western blots of SMARCAD1 and ACTIN in mouse ESCs (mES) and mouse EpiSCs (mEpiSC) (D) and in pig naive and primed pluripotent cells (E).
(F) Microarray-derived Smarcad1 expression levels in mouse ESC, EpiSC, and epiblast. P4 and P24 denotes passages 4 and 24, respectively.
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Figure 2. SMARCAD1 Recognizes H3R26Cit In Vitro and Co-localizes with H3R26Cit In Vivo
(A) Binding signals of SMARCAD1 on MODified Histone Peptide Arrays. Each dot represents the binding intensities to a peptide, which is modified with a unique
combination of post-transcriptional modifications, on array 1 (x axis) and array 2 (y axis).
(B) Binding signals on post-translationally modified versus unmodified peptide (log ratio, y axis). All the peptides with a single modification and the unmodified
peptides are shown (columns). If the raw binding signal to a modified peptide was smaller than the average binding signal to background peptides, the log ratio
was assigned to 0 (non-informative, columns 1–50). If the raw binding signal was above background, this binding signal was divided by that of another peptide
with identical amino-acid sequence without any modification (y axis, in log scale). One asterisks indicates signal >3-fold background in one array. Two asterisks
indicate signal >3-fold background in both arrays.
(C) Relative levels (y axis) of co-localization of SMARCAD1 and each epigenetic modification (x axis), using the entire genome (blue bars) or OCT4 (orange bars) as
the controls. Odds ratio >1 or <1 corresponds to an increased level or a decreased level, respectively, of co-localization.
(D) Cumulative counts of overlaps (y axis) of SMARCAD1 and H3R26Cit peaks, ordered by the significance (MACS-reported p value) of H3R26Cit peaks (x axis).
Red curve shows the overlaps from a permutation analysis where SMARCAD1 peaks were randomly shifted to other genomic locations while keeping the size of
each peak and the locations of the H3R26Cit peaks.
Error bars represent SEM.

including H3K27ac (Figure 2C, orange bars). In particular, the
extent of H3K27ac-SMARCAD1 co-localization does not clearly
exceed that of H3K27ac-OCT4 (odds ratio z 1; orange bar in
H3K27ac column of Figure 2C), suggesting that H3K27ac may
generally enhance protein-chromatin interactions, but such an
effect is not specific to SMARCAD1. The only exception among
the ten analyzed histone marks was H3R26Cit, which exhibited
stronger genomewide co-localization to SMARCAD1 than
OCT4 (odds ratio = 4.22, p < 10 20, chi-square test) (orange
bar in H3R26Cit column, Figure 2C).
Using MACS (Model-based Analysis of ChIP-Seq; v. 1.4.0 beta)
(Zhang et al., 2008) and immunoglobulin G (IgG) ChIP-seq as control, we identified a total of 363 H3R26Cit peaks in the genome.
Among them, 22% (79 peaks) were bound by SMARCAD1, which
correspond to an approximately 300-fold enrichment of overlap
than what is expected from an independence model (1,279
SMARCAD1 peaks in the genome, covering 1 million bases,
approximately 1/1,800 of the effective genome); odds ratio >
300, p < 10 10, chi-square test (Figure 2D). Moreover, 34%,
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42%, and 48% out of the top 150, top 100, and top 50 H3R26Cit
peaks, respectively, overlapped with SMARCAD1 peaks, suggesting that the more significant H3R26Cit peaks were more preferentially bound by SMARCAD1 (Figure 2D).
Phenotypic Differences between Smarcad1 Knockdown
and Naive ESCs
We asked whether SMARCAD1 expression relates to naive-state
pluripotency. To test this, we knocked down Smarcad1 (Smarcad1 knockdown [KD]) in naive ESCs with two different short
hairpin RNA (shRNA) constructs. These constructs reduced
Smarcad1 mRNA to 42% of the original level, on average (Figure 3E), and resulted in decreased protein levels (Figure 3F).
We examined cell morphology, alkaline phosphatase (AP) activity, energy metabolism, contribution to ICM in chimeras, switch
of culture condition, and the transcriptome of Smarcad1 KD
cells.
Within 48 hr of shRNA transfection, mouse ESCs lost their
typical morphology of compact, rounded colonies and exhibited

Figure 3. Smarcad1 KD in Mouse ESCs
(A and B) Mouse ESCs transfected with a control shRNA (A) and a Smarcad1-targeting shRNA (B).
(C and D) AP staining of control (C) and Smarcad1 KD cells (D).
(E) RT-PCR-derived expression fold changes between Smarcad1 KD and control KD cells (Control). Error bars were derived from three biological replicates.
(F) Western blots. pSuper, empty vector control; Luci, control knockdown; RNAi1 and RNAi2, two shRNAs targeting different parts of Smarcad1 mRNA.
(G) Xist expression measured by qPCR in control (luciferase KD) El16.6 (green), and Smarcad1 KD El16.6 (yellow) ESCs.
(H) Proportions of injected embryos with ICM integration. ES, ESCs.

(legend continued on next page)
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a flattened shape (Figures 3A and 3B). These changes were
consistently observed in the two shRNA transfections (Figures
S3A–S3C). We passaged Smarcad1 KD cells for more than 80
passages and could not observe colonies with the appearance
of differentiation, but flattened, monolayer colonies reminiscent
of EpiSCs (primed state) were persistently observed (Figures
S3A–S3C). A total of 27 out of 30 Smarcad1 KD colonies lost
AP activity (Figure 3C), a marker of self-renewal that is absent
in EpiSCs (Brons et al., 2007), whereas nine out of ten control
(Luciferase KD) colonies retained AP activity (Figure 3D).
Compared to control (luciferase KD), Smarcad1 KD cells exhibited a reduced oxygen consumption rate and an increased
extracellular acidity rate (Figures S4A and S4B), suggesting
greater dependence of glycolysis for energy metabolism (Zhou
et al., 2012). In a female ESC line (EL16.6, established by the
Jeannie Lee lab [Zhao et al., 2008]), Smarcad1 KD cells exhibited
a 2.6-fold increase in Xist expression, as compared to luciferase
KD control (Figure 3G).
We compared the frequencies of the ICM contribution of
chimeric blastocysts using an Oct4-EGFP reporter ESC line
(OGR1). While 90.0% of the embryos (n = 10) injected with
OGR1 exhibited ESC integration to ICM, 55.8% of Smarcad1
KD OGR1-injected embryos (n = 43) exhibited ICM integration,
suggesting a reduction of chimeric formation in Smarcad1 KD
cells (p = 0.04, Fisher’s exact test) (Figures 3H and S4C–S4E).
In summary, Smarcad1 KD ESCs exhibited phenotypic differences compared to naive ESCs in cell morphology, AP activity,
energy metabolism, and capacity of forming chimeras. Moreover, these phenotypic assays were carried out without transferring the cells to an EpiSC culture condition (with fibroblast
growth factor 2 [FGF2] and ACTIVIN-A, without leukemia inhibitory factor [LIF]) (Wu et al., 2015), suggesting that it is unlikely that
the observed phenotypic differences were due to environmental
differences. Therefore, by controlling for the culture condition,
Smarcad1 KD cells maintained in ESC culture may offer a unique
opportunity to dissect the genetic factors responsible for naive
pluripotency.
Finally, we moved cells from the ESC culture condition (with
LIF) into the EpiSC culture condition (with FGF2 and ACTIVIN-A,
without LIF) (Wu et al., 2015). After changing to the EpiSC culture
condition, control (luciferase KD) E14 ESCs exhibited a differentiated cell morphology at passage 5 (Figure 3I). In comparison,
Smarcad1 KD E14 ESCs kept their monolayer, human ESC-like
morphology at the same passage (Figure 3J). This suggests
that Smarcad1 KD and control ESCs respond differently to
FGF2/ACTIVIN-A signaling. We note that all other characterizations of the Smarcad1 KD cells in the rest of this paper were
carried out in the ESC culture condition (with LIF) (Li et al.,
2011) for the purpose of teasing out the direct effects of Smarcad1 expression change.
Smarcad1 KD ESCs Retain Pluripotency Characteristics
We asked whether Smarcad1 KD ESCs lost pluripotency. Realtime qPCR analysis showed no expression differences of pluripo-

tency markers Oct4, Nanog, and Sox2 in Smarcad1 KD cells (passage 50) and in control ESCs (passage 50) (Figure 3E). Subjected
to an embryoid body (EB) formation assay, Smarcad1 KD cells
(passage 35) formed EBs that were morphologically indistinguishable from those formed by control cells (passage 35) (Figures S5D
and S5E). Marker genes of all three germ layers, including Mtap2,
Nestin, Cd31, T, Flk-1, Gata4, Afp, Ihh, and Gata6, were expressed 5 to 1,500 times higher in 16-day EBs than in ESCs but
at similar levels in control EBs and in SMARCAD1 KD ESC-derived EBs (Figure S5F). No discernable difference in cell proliferation rates was identified between Smarcad1 KD cells and control
(luciferase KD) cells (Figures S5B and S5C).
To test teratoma formation, we injected four mice with Smarcad1 KD cells (passage 55) and control ESCs (passage 55).
The total numbers of tumors formed were the same (i.e., seven)
for Smarcad1 KD and control cells (Figures S5G and S5H; Table
S1). In the teratomas originating from Smarcad1 KD cells, we
found characteristic cell types and tissues of all three germ
layers, including neural cells, the neural tube, keratin pearl, cartilage, striated muscle, and ciliated epithelium (Figure 3K). Collectively, the expression of pluripotency markers and the formation
of EBs and teratomas suggest that Smarcad1 KD ESCs maintained the capacity for pluripotent lineage specification.
Transcriptome of Smarcad1 KD Cells in ESC Culture
It remains impossible to dissect the genetic regulators of naiveto-primed transition from environmental regulators, because,
in vitro, naive or primed cells have to be maintained in their
respective culture conditions and, in vivo, these cells are
exposed to different signals as well (Han et al., 2010). We assayed the transcriptomes of control (naive) and Smarcad1 KD
ESCs cultured in ESC medium using microarrays and RNA-seq
and compared them with published gene expression data of
EpiSCs cultured in EpiSC medium and wild-type ESCs (naive)
cultured in ESC medium (Tesar et al., 2007; Factor et al., 2014;
Huang et al., 2014). Because our Smarcad1 KD cells were
maintained in ESC medium, we did not expect the expression
differences between Smarcad1 KD cells and ESCs to exhibit genomewide correlations to the expression differences between
EpiSCs (in EpiSC culture) and ESCs (in ESC culture); however,
the data exhibited a moderate genomewide correlation (Figures
S3F and S3G) (Supplemental Analysis). In particular, Smarcad1
KD cells in ESC culture exhibited reduced expression of naive
pluripotency markers Klb, Tbx3, Bmp4, Tfcp2l1, Tet2, Piwil2,
Klf4, Stra8, Fgf4, Wnt6, Esrrb, Pecam1, and Zfp42, and they exhibited increased expression of primed-state markers Smad3,
Fgf8, Lefty1, Pitx2, Fgf5, Pim2, and Fabp7 (Figure S3D). In addition, nine genes in the ACTIVIN/TGF-b (transforming growth factor b) pathway were upregulated in Smarcad1 KD cells, making
the TGF-b pathway the only signaling pathway that was statistically enriched with differentially expressed genes (Fisher’s test,
p < 0.001; Figure S3E). Activation of the ACTIVIN/TGF-b signal
is another hallmark of the primed state, but previously reported
changes in this pathway were compounded with changes of

(I and J) Control (luciferase KD) (I) and Smarcad1 KD (J) ESCs cultured under EpiSC culture condition.
(K) Tissues and cell types identified by histological staining of EBs derived from SMARCAD1 KD E14 ESCs.
Scale bars, 100 mm in (A)–(D) and (I)–(K).
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Figure 4. Epigenomic Difference between Smarcad1 KD Cells and ESCs
(A) H3K4me3 changes (log ratio) between Smarcad1 KD cells and control ESCs (ES) (x axis) versus H3K4me3 changes (log ratio) between EpiSCs and ESCs
(y axis). Each dot represents an H3K4me3 peak identified in either EpiSCs or ESCs. 27,431 peaks (the union of 16,115 peaks in ESCs and 28,431 peaks in EpiSCs)
are plotted.
(B and C) Average H3K4me3 ChIP-seq intensities (y axis) in Smarcad1 KD cells (red), ESCs (green), and EpiSCs (yellow) in a total of 565 Smarcad1 KD-induced
peaks (B) and a total of 496 Smarcad1 KD-repressed peaks (C).
(D) H3K27ac differences between Smarcad1 KD cells and ESCs (x axis) versus H3K27ac changes between EpiSCs and ESCs (y axis) on the union of H3K27ac
peaks (43,797) identified from EpiSCs and ESCs.
(E) H3K27ac distribution near the Kdm5b locus in ESCs, Smarcad1 KD cells, and EpiSCs, marked with previously (Factor et al., 2014) identified ESC-specific
peaks (blue) and EpiSC-specific peaks (pink). H3K27ac in Smarcad1 KD exhibited reduced signals in three ESC-specific peaks and increased signals in the
EpiSC-specific peak (marked with arrows). A new H3K27ac peak was identified (yellow), where both EpiSCs and Smarcad1 KD cells exhibited increased signals
as compared to ESCs.
(F and G) Western blots of H3K9me2 (F) and H3K9me3 (G) in control (luciferase KD) and Smarcad1 KD (KD) mouse ESCs.
(H) Average H3K9me3 ChIP-Seq signals (read counts per 5 3 107 reads) in ESCs (blue) and Smarcad1 KD cells (red) are plotted against the distances to peak
centers (x axis, peak center = 0) of nine chromatin-binding proteins (rows). A total of 10,000 random genomic locations are also included (Random regions).

external signals (Brons et al., 2007; Merrill, 2012). Finally, neither
Cdkn1a (a.k.a. P21) nor Cdkn2a (a.k.a. P16) exhibited increased
expression, which suggested that these cells were unlikely to
have undergone senescence (Figure S5A).
Histone Modification Changes Induced by Smarcad1 KD
In order to characterize Smarcad1 KD-induced histone modification changes, we carried out ChIP-seq on H3K4me3 and
H3K27ac in Smarcad1 KD cells (in ESC medium) and compared
them with published ChIP-seq datasets in EpiSCs (in EpiSC medium) and ESCs (in ESC medium). Using published H3K4me3
ChIP-seq (GEO: GSM1382218), we identified a total of 27,431

peaks from EpiSCs or ESCs and calculated modification intensity in each peak. We compared the ratio of modification intensities between EpiSCs and ESCs (Figure 4A, y axis) to the ratio
between Smarcad1 KD cells and ESCs (Figure 4A, x axis). The
ratios between EpiSCs and ESCs are correlated with that between Smarcad1 KD cells and ESCs in a genomewide manner
(Figure 4A, p < 10 15). Next, we identified the genomic regions
with strong induction of H3K4me3 in Smarcad1 KD (KD-induced
peaks) and those with strong repression (KD-suppressed
peaks). H3K4me3 in EpiSCs exhibited increased intensities in
KD-induced peaks (Figure 4B) and reduced intensities in KDsuppressed peaks (Figure 4C). Taken together, without changing
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the culture condition, suppression of Smarcad1 expression in
ESCs makes the genomewide distribution of H3K4me3 shift toward that in EpiSCs.
We identified a total of 43,797 H3K27ac peaks in either EpiSCs
or ESCs (GEO: GSM1382218). The ratio of H3K27ac intensities
between EpiSCs and ESCs (Figure 4D, y axis) is correlated
with that between Smarcad1 KD cells and ESCs in a genomewide manner (Figure 4D, x axis, p < 10 15). In particular, we
examined the Kdm5b gene locus, which was the main example
where difference in H3K27ac was observed between EpiSCs
and ESCs (see Figure 2 in Factor et al., 2014). Factor et al.
(2014) identified one EpiSC-specific and five ESC-specific
H3K27ac peaks. Smarcad1 KD cells exhibited H3K27ac decrease on three out of the five ESC-specific peaks (Figure 4E,
blue regions) and H3K27ac increase on the EpiSC-specific
peak (Figure 4E, pink region). These data suggest that Smarcad1
KD shared some, but not all, enhancer switches with EpiSCs, as
indicated by H3K27ac changes. In addition, we identified a new
EpiSC-specific peak at the Kdm5b locus (Figure 4E, yellow bar),
which exhibits increased H3K27ac in both EpiSCs and Smarcad1 KD cells. Taken together, H3K27ac changes between
Smarcad1 KD cells and ESCs correlate with the changes between EpiSCs (in EpiSC medium) and ESCs (in ESC medium).
SMARCAD1 Binding Modulates H3K9me3 at a Subset of
SMARCAD1-Binding Sites
We explored the downstream components of the proposed
SMARCAD1-chromatin interaction. ChIP-seq data suggested
moderate co-localization of SMARCAD1 and H3K9me3 (Figure 2C, H3K9me3 columns). To assess the biological significance, we used SETDB1-H3K9me3 co-localization as a positive
control, because H3K9 methyltransferase SETDB1 was thought
to co-localize with H3K9me3 in mouse ESCs (Schultz et al.,
2002; Karimi et al., 2011). Compared to SETDB1, SMARCAD1
ChIP-seq peaks exhibited larger overlaps with H3K9me3
peaks (Figures S2C and S2D), suggesting that the extent of
SMARCAD1-H3K9me3 co-localization was not trivial. Considering that SMARCAD1 does not recognize H3 tail with
H3K9me3 in vitro (Figure 2B, column 17), we posited that
H3K9me3 is downstream to SMARCAD1 binding to chromatin.
To test this, we started by comparing the total amounts of
H3K9me2 and H3K9me3 in wild-type and Smarcad1 KD ESCs,
which revealed no discernable difference (Figures 4F, 4G, and
S2G). Next, we carried out H3K9me3 ChIP-seq in Smarcad1
KD cells and compared it to H3K9me3 ChIP-seq data in ESCs.
There was no discernable difference of H3K9me3 modification
levels in 10,000 randomly selected genomic regions (Figure 4H),
which is consistent with the western blot data (Figures 4F and
4G). In addition, there was no discernable difference in the
ChIP-seq peaks of OCT4, NANOG, and CTCF (Figure 4H). However, in the 1,279 SMARCAD1 peaks (called with ChIP-seq in
ESCs using MACS v. 1.4.0beta) (Zhang et al., 2008), H3K9me3
modification levels were substantially increased in Smarcad1
KD cells compared to ESCs (p < 10 15, two-tailed t test) (Figure 4H). Furthermore, the largest changes of H3K9me3 precisely
appeared at the centers of the Smarcad1 peaks (Figure 4H,
x = 0). These data suggest that, although there are no global
changes of H3K9me3 in Smarcad1 KD cells, there is an increase
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of H3K9me3 in SMARCAD1-binding regions. These data are
incompatible with an alternative model, where Smarcad1 KD
caused differentiation, which, in turn, resulted in global chromatin condensation and global H3K9me3 increases.
To further assess whether the H3K9me3 changes in
SMARCAD1 peaks were due to reduced SMARCAD1 binding in
the Smarcad1 KD condition, we conducted SMARCAD1 ChIPseq in Smarcad1 KD E14 ESCs. Out of the 1,279 SMACARD1
peaks detected in ESCs, 1,207 (94.4%) exhibited a decrease of
ChIP-seq signal in Smarcad1 KD cells, and 897 (70%) exhibited
a strong decrease (KD sensitive). Among these 897 KD-sensitive
SMARCAD1 peaks, 166 (18.5%) exhibited an increase of
H3K9me3 levels in Smarcad1 KD, 3 (0.33%) exhibited decrease,
and the rest (728) did not exhibit a significant change of H3K9me3
levels. Therefore, although the total amount of H3K9me3 did not
appear to change with Smarcad1 KD, Smarcad1 KD is associated with increased H3K9me3 in a subset of SMARCAD1-binding
regions.
H3Cit Is Negatively Associated with H3K9me3 in
SMARCAD1-Binding Regions
The data led us to speculate a model that SMARCAD1 binding
prevents the formation of extremely dense H3K9me3 regions.
Considering the in vitro binding (Figures 2A and 2B) and in vivo
(Figures 2C and 2D) correlation of SMARCAD1 and H3Cit, the
aforementioned model is consistent with the idea that H3Cit
interferes with H3K9me3-mediated heterochromatin formation (Sharma et al., 2012), and the latter is a characteristic
of ESC differentiation. However, the data do not exclude
H3Cit-independent mechanisms of SMARCAD1 recruitment
to chromatin.
The aforementioned model would predict a negative correlation of H3Cit and H3K9me3 in SMARCAD1-binding regions.
Among the 79 H3R26Cit peaks bound by SMARCAD1 in the
entire genome, 73 (92.4%) exhibited at least a 1.5-fold increase
of H3K9me3 in Smarcad1 KD cells (Figure 5E). In particular, the
genomic loci of naive-state markers Klf4 and Wnt6 exhibited
2-fold more increases of H3K9me3 in Smarcad1 KD cells (Figures S6A and S6B).
To further test the speculated model, we inhibited H3Cit by Clamidine treatment (Christophorou et al., 2014) and carried out
SMARCAD1 ChIP-seq and H3K9me3 ChIP-seq in Cl-amidinetreated (Cl+) cells. Compared to untreated ESCs, SMARCAD1
ChIP-seq signals exhibited mild decreases near H3R26Cit peaks
(H3R26Cit peaks were defined by ChIP-seq in untreated ESCs)
(Figure 5A). Next, we compared H3K9me3 ChIP-seq signals
between Cl+ and untreated ESCs. No discernable H3K9me3
changes were identified in 10,000 randomly selected regions
(Figure 5B). In addition, H3K9me3 ChIP-seq barely exhibited
any changes in OCT4, NANOG, CTCF, H3K4me1, and
H3K4me3 peaks (defined in untreated ESCs) either (Figure 5C).
However, H3K9me3 exhibited strong increases in H3R26Cit
peaks (defined in untreated ESCs) and in SMARCAD1 peaks
(defined in untreated ESCs), lending additional support to the
hypothesized roles of H3Cit and SMARCAD1 (Figure 5D and
5E). Furthermore, in the overlapped peaks of H3R26Cit and
SMARCAD1 (defined in untreated ESCs), H3K9me3 exhibited
even greater increases than those in H3R26Cit peaks or in

Figure 5. SMARCAD1 and H3K9me3 Changes in Cl-Amidine Treatment
(A) SMARCAD1 ChIP-seq intensities in Cl-amidinetreated (Cl+) cells and untreated ESCs (ES).
(B–F) H3K9me3 ChIP-seq intensities in Cl+ cells and
ESCs in 10,000 random genomic regions (B); OCT4,
NANOG, CTCF, H3K4me3, and H3K4me1 ChIP-seq
peaks (C); H3R26Cit peaks (D); SMARCAD1 peaks
(E); and the overlaps of H3R26Cit and SMARCAD1
peaks (F). All peaks were defined by ChIP-seq in
ESCs.
(G) A genome browser view of H3R26Cit,
SMARCAD1, H3K9me3 ChIP-seq in ESCs; H3K9me3
in Smarcad1 KD cells; H3K9me3 in Cl+ ESCs; and
IgG ChIP-seq and MNase-seq (sequencing of input
DNA fragmented by micrococcal nuclease [MNase])
in ESCs.

from 2i medium into LIF-based culture
condition (with LIF, and without 2i, as
described in Li et al. [2011]), cultured
them for 48 hours, and then performed
SMARCAD1 ChIP-seq.
DISCUSSION

SMARCAD1 peaks (Figure 5F). The specific H3K9me3 changes
in SMARCAD1 peaks are also incompatible with the alternative
model mentioned earlier.
Reproducibility of Genomewide SMARCAD1 Binding in
Male and Female ESCs
To assess the variation of ChIP-seq data in different ESC lines,
we generated SMARCAD1 ChIP-seq from a female ESC line
derived by Wu et al. (Wu1) from C57BL mice (Wu et al., 2015)
and compared it to E14 (derived from a male 129X1 mouse)
data. In order to make an unbiased comparison, we fragmented
the mouse genome (mm9) into 500-nt bins. After removing the
bins with low mappability, we retained 4,854,116 bins. We
calculated the ratio between SMARCAD1 and IgG ChIP-seq
reads (SMARCAD1/IgG) in every bin and compared these ratios
between the two ChIP-seq datasets. SMARCAD1 ChIP-seq in
E14 and Wu1 cells exhibited a degree of correlation (Pearson
correlation = 0.378) comparable to that of two H3K27me3
ChIP experiments conducted in the same cell line (Pearson correlation = 0.359) (Kaneko et al., 2013; Xiao et al., 2012) and that
of two ESC ESET (H3K9 methyltransferase, ERG-associated
protein with SET domain) ChIP-seq experiments (Pearson correlation = 0.344) (Yuan et al., 2009; Bilodeau et al., 2009; Figure 6). A caveat of this analysis is that Wu1 ESCs were cultured
in the 2i condition (Wu et al., 2015). We transferred Wu1 cells

A Candidate System for Dissecting
Genetic and Environmental
Regulators of Naive-To-Primed
Transition
It has been 10 years since the initial derivation and characterization of cultured
primed-state pluripotent stem cells
(Brons et al., 2007; Tesar et al., 2007). It remains extremely
difficult to analyze the earliest genetic factors that underscore
the naive-to-primed transition, because naive and primed cells
are exposed to different signals either in vivo or in vitro (Han
et al., 2010; Weinberger et al., 2016).
H3Cit was reported to correlate with the naive pluripotent
state (Christophorou et al., 2014), but inhibition of H3Cit may
not be an ideal system for studying naive-to-primed transition,
because it resulted in cell differentiation as seen in global chromatin compaction, induction of differentiation markers, and
reduction of Nanog mRNA expression to one-third that of the
control ESCs (Christophorou et al., 2014). Compared to H3Cit
inhibition, Smarcad1 KD phenotypes were more delicate. On
one hand, Smarcad1 KD cells remain capable of pluripotent
lineage specification; on the other hand, Smarcad1 KD ESCs
lost representative cellular features of the naive state, even
when they remain in ESC culture medium. This unique property
makes Smarcad1 KD ESCs a candidate for the desired in vitro
system.
H3Cit was thought to prevent heterochromatin formation by
weakening H3K9me3 (Sharma et al., 2012); however, the
mechanism was unknown. The histone modification changes
in Smarcad1 repression and H3Cit inhibition conditions—especially the stepwise increases of H3K9me3 from other genomic regions to H3R26Cit peaks and SMARCAD1 peaks and then to

Cell Reports 18, 3117–3128, March 28, 2017 3125

Figure 6. Variation of SMARCAD1 ChIP-Seq
in Male and Female ESCs
(A–C) The mappable portion of the genome (mm9)
was separated into a total of 4,854,116 nonoverlapping 500-bp bins. A subset of 5,000 bins
was drawn at random for plotting.
(A) Scatterplot of the ratio of SMARCAD1 and IgG
ChIP-seq reads in 500-bp bins in E14 (male, x axis)
and in Wu1 (female, y axis).
(B) Scatterplot between two biological replicates
(GSM1199184 on the y axis, and GSM2111307 on
the x axis). Each dot is a ratio of H3K27me3 and
IgG ChIP-seq reads in a 500-bp bin.
(C) Scatterplot of ratio between ESET ChIP-seq
and IgG ChIP-seq reads in E14 (GSM440256)
(x axis) and V6.5 (GSM459273) (y axis) ESCs.
(D) Genome browser view of SMARCAD1 ChIPseq in E14 and Wu1 cells, and H3K9me3 in E14
and in Smarcad1 KD cells (E14-KD). MNaseseq, sequencing of input DNA fragmented by
MNase.
(E) A speculated model for the role of SMARCAD1
in regulating the naive pluripotent state. Naive
pluripotent, primed pluripotent, and differentiated
cells are situated on an epigenetic landscape
(dark curve). In this model, SMARCAD1 contributes to keep cells at the highest position on the
epigenetic landscape by translating H3Cit into an
inhibitory signal of H3K9me3.

H3R26Cit/SMARCAD1 overlapping peaks—suggest SMARCAD1
could be a missing link of H3Cit-mediated suppression of
H3K9me3 (Figure 6E).
Other Possible Mechanisms for SMARCAD1
Recruitment to Chromatin
The aforementioned data do not rule out H3Cit-independent
mechanisms for SMARCAD1 recruitment to chromatin. The
lack of DNA-binding specificity in vitro does not rule out the scenario where SMARCAD1 is tethered to chromatin by co-factors.
LTR (long terminal repeat) retrotransposons and satellite repeats appear more frequently in SMARCAD1 peaks than in
the entire genome (see Supplemental Analysis). In addition,
SMARCAD1 may interact with histone deacetylase HDAC1
(Rowbotham et al., 2011), which may explain why SMARCAD1
binds to H3K27ac in vitro but SMARCAD1 binding only moderately correlates with H3K27ac in vivo. Furthermore, the peptide
array data suggest that H3 S28 phosphorylation (H3S28P) inhibits SMARCAD1 binding to H3 in vitro (Figure S1), which suggests that combinatorial histone modifications could affect
SMARCAD1 interaction with chromatin. Finally, we did not
find a correlation between nucleosome positions (Chen et al.,
2013) and SMARCAD1 binding. Nucleosome phase lengths
were slightly reduced in SMARCAD1 peaks, but they did not
exhibit clear differences between SMARCAD1-associated
H3R26Cit peaks and the entire genome (Figure S2E).
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Open-Chromatin versus ClosedChromatin Hypotheses
H3Cit was thought to interfere with
H3K9me3-mediated heterochromatin formation (open-chromatin hypothesis) (Sharma et al., 2012),
whereas SMARCAD1 was thought to associate with and promote H3K9me3, a mark of closed chromatin (closed-chromatin
hypothesis) (Rowbotham et al., 2011). At a first glance, the opposite effects do not seem to allow a simple model that directly puts
H3K9me3 downstream to the proposed H3R26Cit/SMARCAD1
pathway. The increase of H3K9me3 in Smarcad1 KD cells on
H3R26Cit peaks is better aligned with the open-chromatin hypothesis. In addition, the closed-chromatin hypothesis primarily
relied on the observation of strong decreases of the total
amounts of H3K9me2 and H3K9me3 in the Smarcad1 KD condition (Rowbotham et al., 2011). We carried out the same test in
ESCs. The total amounts of H3K9me2 and H3K9me3 did not
decrease in Smarcad1 KD ESCs, as compared to control
ESCs, in multiple independent experiments (Figures 4F and
4G). These different results are potentially attributable to celltype differences. In summary, at least in naive ESCs and on
H3R26Cit peaks, SMARCAD1 binding may function as a checkpoint, which prevents the formation of overly dense H3K9me3
regions.
H3K9me3 changes in the genomic loci of naive pluripotency
markers may not be the only plausible explanation of Smarcad1
KD induced change of pluripotent state. An non-exclusive
alternative hypothesis is that SMARCAD1 binding mediated suppression of H3K9me3 keeps certain retrotransposons transcriptionally active, which is a feature of increased developmental

potency and is correlated to an earlier developmental stage
(Macfarlan et al., 2012). Consistent to this hypothesis, LTR retrotransposons were enriched in SMARCAD1-binding regions and
also enriched in Smarcad1-KD-induced H3K9me3 peaks (Supplemental Analysis). Interestingly, deletion of an H3K9 methyltransferase upregulated a set of LTR retrotransposons and their
nearby genes (Karimi et al., 2011).
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Change of Culture Condition
Under the ESC culture condition with LIF (Li et al., 2011), we carried out
shRNA-mediated Smarcad1 KD and Luciferase KD (control). After 6 days of
puromycin selection in ESC culture, the cells were transferred onto Matrigelcoated plates with EpiSC culture medium as previously described (Wu et al.,
2015). Briefly, the EpiSC medium is composed of N2B27 basal medium and
20% knockout serum replacement (KSR), 12 ng/mL FGF2, and 2 ng/mL
ACTIVIN-A.
Quantifying Genomewide Co-localization of Two Histone
Modifications
Odds ratio was used to measure the extent of co-localization between two histone modifications, as previously described (Xiao et al., 2012). Briefly, the
genome was split into 200-nt non-overlapping bins. Each histone modification
was judged as either present or absent on each bin based on ChIP-seq data. A
contingency table was built for the distribution of genomic bins, reflecting the
presence and absence of each histone modification. Odds ratio was calculated based on this contingency table. The odds ratio larger or smaller than
1 reflects more or fewer overlaps of the two histone modifications than random
expectation. The odds ratio between a chromatin-binding protein and a
histone modification was calculated by the same approach, where one
ChIP-seq dataset of histone modification was replaced by that of the chromatin-binding protein.
CI-Amidine Treatment
Cl-amidine treatment of ESCs was carried out as previously described (Christophorou et al., 2014). Briefly, Cl-amidine (200 mM) was added to ESC culture
medium, and E14 ESCs were maintained in this treatment condition for
48 hours. Approximately 10 million treated cells were crosslinked for each
ChIP-seq experiment. Approximately 3 million treated cells were obtained at
the same time for western blot experiments.
Additional materials and methods are available in the Supplemental Experimental Procedures.
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